403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Biotechnology CMO And CDMO Market On Track For USD 199.67 Billion By 2034 With A Strong 11.54% CAGR
| Table | Scope | |
| Market Size in 2025 | USD 74.01 Billion | |
| Projected Market Size in 2034 | USD 199.67 Billion | |
| CAGR (2025 - 2034) | 11.54 | % |
| Leading Region | North America by 42% | |
| Market Segmentation | By Service Type, By Product Type, By Scale of Operation, By Technology Platform, By End User, By Region | |
| Top Key Players | Thermo Fisher Scientific (Patheon), Boehringer Ingelheim BioXcellence, Rentschler Biopharma SE, AGC Biologics, AbbVie Contract Manufacturing, KBI Biopharma, Emergent BioSolutions, Minaris Regenerative Medicine, Vibalogics (Recipharm), Charles River Laboratories (Biologics CDMO unit), Ajinomoto Bio-Pharma Services, Binex Co., Ltd., Evotec SE (Biologics CDMO division), Thermo Fisher Viral Vector Services, Cognate BioServices |
What is the Growth Potential Responsible for The Growth of The Biotechnology CMO and CDMO Market?
The main drivers of the biotechnology CMO and CDMO market are the increasing complexity and volume of biologic drugsWhat are the Growing Trends Associated with the Biotechnology CMO and CDMO Market?
Digitalisation and automation: CDMOs are adopting digital technologies like AI, real-time analytics, and automation to improve process efficiency, enhance quality control, and minimise batch failures.
Strategic partnerships and M&A: The industry is seeing a rise in both long-term strategic partnerships between pharma companies and CDMOsShift toward integrated services: There is a growing demand for integrated services that cover the entire process from development through to commercial manufacturing.
Focus on specialised therapies: CMOs and CDMOs are increasingly developing expertise in manufacturing high-value, small-batch drugs like orphan drugs and precision medicineNavigating complexity: The growing complexity of global supply chains and regulatory requirements is creating opportunities for CDMOs that can provide reliable, high-quality manufacturing services across different markets.
What is the Challenge in the Biotechnology CMO and CDMO Market?
Key challenges facing the biotechnology CMO and CDMO market include navigating complex and evolving global regulations, high capital investment for specialised facilities and technology, supply chain disruptions, a shortage of skilled personnel, and the need to protect intellectual property. Additionally, intense market competition, especially from smaller and emerging companies, and balancing cost with high-value services are significant challenges.
Become a valued research partner with us -Major Government Initiative
| Initiative | Description |
| BioE3 Policy | The "Biotechnology for Economy, Environment and Employment" policy was established to foster high-performance biomanufacturing. |
| Biotechnology Research, Innovation, and Entrepreneurship Development | The government continued this umbrella scheme with new components focused on biomanufacturing and biofoundries. It offers capital grants, seed funding, and other incentives to startups and small to medium-sized enterprises (SMEs). |
| Production Linked Incentive (PLI) Scheme | This program offers financial incentives to pharmaceutical companies that achieve production targets for critical raw materials, biologics, and complex generics. |
| National Biopharma Mission | Co-funded by the World Bank, this mission strengthens India's capabilities in biopharmaceuticals, including vaccines, biosimilars, and diagnostics. |
| BioSecure Act (Pending) | The proposed legislation banning federal funding for U.S. companies working with certain Chinese biotech firms has influenced planning within the CDMO sector throughout 2025. |
Regional Analysis
How Did North America Dominate the Biotechnology CMO and CDMO Market in 2024?
North America was dominant in the Biotechnology CMO and CDMO Market in 2024, with approximately a 42% share. Its dominance is driven by the region's strong base of pharmaceutical and biotech companies, which outsource drug development and manufacturing due to demand for complex products like biologics and cell/gene therapies. Key market drivers include the growing demand for biologics and biosimilars and the trend of outsourcing complex
What Made the Asia Pacific Significantly Grow in The Biotechnology CMO and CDMO Market In 2024?
Asia Pacific is expected to grow at the fastest CAGR from 2025 to 2034. The Asia Pacific biotechnology CMO and CDMO market is experiencing rapid growth, driven by a large population, a high prevalence of chronic diseases, and increasing investments in healthcare. This expansion is fueled by strong demand for biologics and biosimilars, with countries like China and India leading the way. Key factors contributing to this growth include cost-effective manufacturing, rising government support and incentives for foreign investment, and a growing number of smaller biotech firms needing specialised manufacturing services.
Get the latest insights on life science industry segmentation with our Annual Membership:Segmental Insights
By Service Type,
The commercial manufacturing segment was dominant in 2024, with approximately 46% share. Commercial manufacturing services account for the largest share of the biotechnology CMO and CDMO market, focusing on large-scale production of biologics, biosimilars, and advanced therapies. These services ensure GMP compliance, cost-efficiency, and scalability. Demand is driven by biopharma firms
The fill–finish and packaging segment is expected to be the fastest-growing over the forecast period, 2025 to 2034. Fill-finish and packaging are critical stages ensuring product sterility gene therapiesBy Product Type,
The monoclonal antibodies (mAbs) segment was dominant in the market in 2024, with approximately 41% share. Monoclonal antibodies dominate biotechnology outsourcing, owing to their therapeutic relevance in oncology, autoimmune, and infectious diseases. CMOs and CDMOs specialise in high-yield mammalian cell expression systems, purification processes, and analytical testing. The increasing approval of biosimilars and next-generation antibody formats further fuels this segment's growth.
The cell & gene therapies segment is expected to register the fastest growth over the forecast period, 2025 to 2034. Cell and gene therapies represent one of the fastest-growing product categories, requiring specialised manufacturing facilities and regulatory expertise. CDMOs provide end-to-end support, from viral vector production to final fill-finish of autologous and allogeneic products. Strategic partnerships and capacity expansion are increasing to meet the rising demand for personalised medicine Get the latest insights on life science industry segmentation with our Annual Membership:By Scale of Operation,
The commercial scale segment was dominant in the biotechnology CMO and CDMO market in 2024, with approximately 53% share. Commercial-scale manufacturing supports large-volume production for approved biologics and biosimilars. CDMOs focus on maintaining consistency, quality assurance, and global regulatory compliance. Integration of digital biomanufacturing and process intensification technologies enhances yields and reduces timelines, catering to established pharmaceutical companies seeking cost-effective global supply chains.
The flexible/hybrid manufacturing segment is expected to register the fastest growth over the forecast period, 2025 to 2034. Flexible or hybrid manufacturing combines small- and large-scale capacity for multiproduct operations. This approach allows rapid adaptation to variable demand, especially for emerging biotechs and mid-sized pharma companiesBy Technology Platform,
The mammalian cell culture segment was dominant in the market in 2024, with approximately 48% share. Mammalian cell culture remains the backbone of biologics manufacturing, particularly for antibodies, fusion proteins, and recombinant therapeutics. CMOs and CDMOs invest in high-density perfusion systems and advanced upstream technologies to boost productivity. Regulatory compliance and process scalability are key factors driving sustained adoption across commercial-scale production.
The cell & gene therapy platforms segment is expected to register the fastest growth over the forecast period, 2025 to 2034. The cell and gene therapy platform includes viral vector production, cell processing, and genome editing workflows. Specialised CDMOs provide capabilities for GMP manufacturing, plasmid production, and cryogenic logistics. The segment is growing rapidly due to expanding clinical pipelines, FDA approvals, and investment in next-generation therapeutic modalities.
By End User,
The large pharmaceutical companies segment was dominant in the biotechnology CMO and CDMO market in 2024, with approximately 47% share. Large pharmaceutical companies rely heavily on CDMOs for scaling biologics and gene therapy production. Outsourcing reduces operational complexity and capital expenditure while ensuring regulatory compliance and consistent supply. Strategic partnerships and long-term contracts are common, enabling faster global market access for innovative biopharmaceuticals.
The biotechnology companies segment is expected to register the fastest growth over the forecast period, 2025 to 2034. Biotechnology companies, often focused on R&D and early-stage innovation, use CDMOs for end-to-end manufacturing solutions. They benefit from flexible capacity, technical expertise, and regulatory support without the need for in-house infrastructure. Growing investment in novel biologics and gene-based therapies continues to expand outsourcing opportunities in this segment.
Browse More Insights of Towards Healthcare:
The global biotechnology and pharmaceutical services market
The biotechnology reagents and kits market
The biotechnology instruments market
The marine biotechnology market
The APAC biotechnology market
The AI in biotechnology market
The agricultural biotechnology market
The global animal biotechnology market
The nanobiotechnology market
The U.S. biotechnology market
Recent Developments
- In April 2025, Novartis announced plans to acquire Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The acquisition aims to strengthen Novartis's pipeline in RNA-targeted therapies. Under the terms of the agreement, Novartis will pay an upfront cash amount of $7 per share, totalling approximately $800 million. In February 2025, CDMO Live has emerged as the definitive industry gathering, bringing together Europe's leading pharmaceutical outsourcing decision-makers at Rotterdam's World Trade Centre this May, putting the spotlight on this critical sector.
Biotechnology CMO and CDMO Market Key Players List
- Thermo Fisher Scientific (Patheon) Boehringer Ingelheim BioXcellence Rentschler Biopharma SE AGC Biologics AbbVie Contract Manufacturing KBI Biopharma Emergent BioSolutions Minaris Regenerative Medicine Vibalogics (Recipharm) Charles River Laboratories (Biologics CDMO unit) Ajinomoto Bio-Pharma Services Binex Co., Ltd. Evotec SE (Biologics CDMO division) Thermo Fisher Viral Vector Services Cognate BioServices
Biotechnology CMO and CDMO Market – Value Chain Analysis
R&D
Various R&D processes involved in biotechnology CMO and CDMO, such as the exploration and manipulation of biological systems and living organisms to create new solutions.
Key Players: ALTEN and Cheesecake Labs
Clinical Trials
Outsource manufacturing adheres to strict government guidelines, specifically present good manufacturing practices (cGMP), to confirm the quality, safety, and integrity of the Investigational Medicinal Product (IMP) through the clinical trial phases
Key Players: Qubit Labs and Riseup Labs
Patient Services
Biotech contract manufacturing majorly focuses on manufacturing drug substances and drug products for a client organization. Patient services are managed by the client's biotech or pharmaceutical company.
Key Players: NE and Tata Consultancy Services
Top Vendors and their Offering
- Lonza Group: Access end-to-end integrated biologics development services from pre-clinical to commercialization, for drug substance and drug product. Samsung Biologics: Samsung Biologics is a reliable partner for seamless tech transfers, clinical and commercial biologics manufacturing, aseptic fill-finish, and analytical testing. WuXi Biologics: As a premier Contract Development and Manufacturing Organization, WuXi STA offers our worldwide partners efficient, flexible, and high-quality solutions for integrated CMC from preclinical to commercial. Catalent Inc.: Catalent Biologics' drug product CDMO services leverage advanced technologies and proven expertise to supply better biologics, biosimilars, vaccines, sterile injectables, and diluents to your patients. Fujifilm Diosynth Biotechnologies: FUJIFILM Biotechnologies provides process development through to commercial supply of life-impacting medicines for patients around the world.
Segments Covered in The Report
By Service Type
- Process Development Analytical & Quality Testing Clinical Manufacturing Commercial Manufacturing Fill–Finish & Packaging Regulatory & Technical Services
By Product Type
- Monoclonal Antibodies (mAbs) Recombinant Proteins Vaccines Cell & Gene Therapies RNA-based Therapies (mRNA, siRNA, saRNA) Biosimilars Others
By Scale of Operation
- Preclinical/Small Scale Clinical Scale Commercial Scale Flexible/Hybrid Manufacturing
By Technology Platform
- Mammalian Cell Culture Microbial Fermentation Cell & Gene Therapy Platforms RNA Manufacturing Platforms Others
By End User
- Large Pharmaceutical Companies Biotechnology Companies Academic & Research Institutes Contract Research Organisations (CROs) leveraging CMOs/CDMOs
By Region
- North America
- U.S. Canada
- China Japan India South Korea Thailand
- Germany UK France Italy Spain Sweden Denmark Norway
- Brazil Mexico Argentina
- South Africa UAE Saudi Arabia Kuwait
Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard:About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research You can place an order or ask any questions, please feel free to contact us at ...Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region: +91 9356 9282 04
Web:Our Trusted Data Partners
Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment